AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Silexion Therapeutics Corp Ordinary Shares
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG01PBJB8F3
0.19▲ 0.02 (14.32%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
0.17
Day's Range
0.16 – 0.20
52-Week Range
0.14 – 5.45
Volume
2.4M
Avg Volume
14.3M
Share Statistics
Shares Outstanding
Employees
13
Exchange
XNAS
Listed
2024-08-16
Share count as of August 13, 2026

Silexion Therapeutics Corp Ordinary Shares (SLXN) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Silexion Therapeutics Corp Ordinary Shares (SLXN)
What is Silexion Therapeutics Corp Ordinary Shares's Market Cap?
Silexion Therapeutics Corp Ordinary Shares's Market Cap is $1.1M, based on as-reported figures from SEC (XBRL) filings.
What is Silexion Therapeutics Corp Ordinary Shares's Enterprise Value?
Silexion Therapeutics Corp Ordinary Shares's Enterprise Value is -$1.2M, based on as-reported figures from SEC (XBRL) filings.
What is Silexion Therapeutics Corp Ordinary Shares's EV / EBITDA?
Silexion Therapeutics Corp Ordinary Shares's EV / EBITDA is 0.1×, based on as-reported figures from SEC (XBRL) filings.
What is Silexion Therapeutics Corp Ordinary Shares's Net Income (TTM)?
Silexion Therapeutics Corp Ordinary Shares's Net Income (TTM) is -$14.0M, based on as-reported figures from SEC (XBRL) filings.
What is Silexion Therapeutics Corp Ordinary Shares's EBITDA?
Silexion Therapeutics Corp Ordinary Shares's EBITDA is -$14.1M, based on as-reported figures from SEC (XBRL) filings.
What is Silexion Therapeutics Corp Ordinary Shares's Diluted EPS (TTM)?
Silexion Therapeutics Corp Ordinary Shares's Diluted EPS (TTM) is -2.51, based on as-reported figures from SEC (XBRL) filings.
What is Silexion Therapeutics Corp Ordinary Shares's Net Debt?
Silexion Therapeutics Corp Ordinary Shares's Net Debt is -$2.2M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · SLXNAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023
Research and development (including $176 and $0 from related party for the six-month periods ended June 30, 2026 and 2025, respectively, and including $46 and $0 from related party for the three months period ended June 30, 2026 and 2025, respectively)
General and administrative (including $282 and $58 from related party for the six-month periods ended June 30, 2026 and 2025, respectively, and including $67 and $37 from related party for the three months period ended June 30, 2026 and 2025, respectively)
TOTAL OPERATING EXPENSES
OPERATING LOSS—
Financial expenses (income), net (including $(169) and $229 from related party for the six months period ended June 30, 2026 and 2025, respectively, and including $(154) and $197 from related party for the three months period ended June 30, 2026 and 2025, respectively)
LOSS BEFORE INCOME TAX
INCOME TAX——
NET LOSS
LOSS PER SHARE, BASIC—
LOSS PER SHARE, DILUTED—